IDEAYA Biosciences (IDYA) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.22

Estimate

-$1.16

Surprise

-4.8%

Revenue (period 2026-09-30)

$10.2M

Score today

4.9/10

Revenue source: xbrl.

IDEAYA Biosciences (IDYA) reported a wider loss than forecast — adjusted EPS of -$1.22 against the -$1.16 estimate (a 4.8% shortfall).

• Wedbush Adjusts Price Target on IDEAYA Biosciences to $63 From $60 — fiscal.ai, 2026-11-03
• IDEAYA Biosciences Reports Third Quarter 2026 Financial Results and Business Update — fiscal.ai, 2026-11-03
• IDEAYA Biosciences Q3 EPS $(1.22) Misses $(1.18) Estimate, Sales $10.242M Beat $6.857M Estimate — benzinga, 2026-11-03

TrendMatrix currently rates IDYA Sell at 4.9/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -4.8% surprise compares with a -8.5% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$31.33

Price target

$45.17

Stop

$30.15

Upside to target

+44.2%

Reward-to-risk

4.6:1

Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$3.02B

P/E (fwd)

-7.7

52-week range

$26.81–$42.68

Off 52-week high

26.6%

RSI (14)

39

Volume vs avg

2.01×

Score today

4.9/10